Investigators in the commercial and non-profit sectors have always faced pressure to accelerate their work while balancing the need for quality and the realities of budget constraints. Pharmaceutical and biotech companies want to speed their time to market with a novel, efficacious therapeutics. Non-profit institutions want to accelerate early-stage work that may lead to the identification of new drug targets or therapeutic approaches. Austin Jelcick at Taconic Biosciences looks at ways to adapt preclinical animal model strategies to achieve research and business objectives.